Latest Product Validation News

Critica Limited has produced a second high-grade rare earth product from its Jupiter Project, achieving 86% total rare earth oxide and confirming the repeatability of its beneficiation process. This milestone reinforces Jupiter's status as Australia's premier rare earth resource amid growing global supply chain concerns.

Papyrus Australia has marked significant progress at its Adelaide R&D facility while its sustainable fibre board gains international recognition, setting the stage for expanded global partnerships.

5E Advanced Materials reports progress on its California boron project with a new feasibility study and equity raises, while highlighting ongoing funding uncertainties.

Critica Limited has marked a significant milestone in its Jupiter rare earths project, commissioning a pilot plant and producing its first high-grade mixed rare earth oxide product, underscoring its path from resource to revenue.

CurveBeam AI reports a 33% increase in Q1 FY26 purchase orders, secures A$6.5 million in new funding, and finalizes a strategic joint venture for China distribution and manufacturing rights.

CurveBeam AI reports a 33% rise in device purchase orders and secures a $6.5 million placement alongside a landmark China distribution partnership. The company advances FDA regulatory milestones and establishes a vendor financing facility to boost sales.

AnteoTech Ltd reported a 110% revenue increase to A$968,878 in FY2025 alongside a 24% reduction in net loss, driven by strategic cost savings and key partnerships. Leadership renewal and product validation position the company for growth in battery and life sciences markets.

Euro Manganese Inc. has bolstered its development of the Chvaletice Manganese Project with new financing and critical regulatory approvals, while progressing offtake discussions amid ongoing market uncertainties.

5E Advanced Materials has released a robust Preliminary Feasibility Study for its Fort Cady Project in California, highlighting a 39.5-year mine life and strong economics with a pre-tax NPV7 of US$724.8 million and a 19.2% IRR.

Rhythm Biosciences has advanced its ColoSTAT® diagnostic kits to final production validation, demonstrating consistent detection of colorectal cancer across all stages in a pivotal study. The company is gearing up for regulatory submission and commercial launch later this year.

Rhythm Biosciences has successfully validated its ColoSTAT® colorectal cancer test, secured its first strategic partnership for Genetype, and secured $1 million in non-dilutive funding, setting the stage for a transformative FY26.

Bio-Gene Technology Limited has secured $2.45 million to fund critical safety studies and scale-up production of its novel insecticides Flavocide and Qcide, positioning the company for upcoming regulatory approvals and commercial partnerships.